{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:44:28Z","timestamp":1785210268261,"version":"3.55.0"},"reference-count":27,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.2217\/fon-2020-1003","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T10:05:33Z","timestamp":1606903533000},"page":"503-515","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["Real-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-9690","authenticated-orcid":false,"given":"Deepu","family":"Madduri","sequence":"first","affiliation":[{"name":"Mount Sinai School of Medicine, \rNew York,NY10029,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-2580","authenticated-orcid":false,"given":"May","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Policy Analysis Inc., \rChestnut Hill,MA02467,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-0012","authenticated-orcid":false,"given":"Kejal","family":"Parikh","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, \rPrinceton,NJ08540,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-5145","authenticated-orcid":false,"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, \rPrinceton,NJ08540,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5493-1925","authenticated-orcid":false,"given":"Thomas E","family":"Delea","sequence":"additional","affiliation":[{"name":"Policy Analysis Inc., \rChestnut Hill,MA02467,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8195-0224","authenticated-orcid":false,"given":"Arianna","family":"Kee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, \rPrinceton,NJ08540,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, \rNew York,NY10029,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"American Cancer Society . Cancer facts and figures 2019. (2020). http:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf"},{"key":"e_1_3_5_4_1","unstructured":"National Comprehensive Cancer Network Inc . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for multiple myeloma (2020). V.3.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1648802"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9040029"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13426"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13046"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0930-x"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.100"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0113"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1031732"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361035"},{"key":"e_1_3_5_22_1","unstructured":"Truven Health Analytics . IBMWatson Health. The Truven Health MarketScan Databases for health services researchers. https:\/\/truvenhealth.com\/portals\/0\/assets\/2017_MarketScan_Databases_Health_Services_Researchers.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"issue":"1","key":"e_1_3_5_24_1","first-page":"221","article-title":"Economic burden of disease progression among transplant eligible multiple myeloma patients who have received at least one line of therapy in the US","volume":"134","author":"Fonseca R","year":"2019","unstructured":"Fonseca R , HagiwaraM, PanjabiSet al. Economic burden of disease progression among transplant eligible multiple myeloma patients who have received at least one line of therapy in the US. Blood134(Suppl. 1), 221 (2019).","journal-title":"Blood"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533947"},{"issue":"1","key":"e_1_3_5_26_1","first-page":"EP1756","article-title":"Recent treatment patterns, healthcare utilization, and costs in heavily pretreated relapsed and\/or refractory multiple myeloma patients in the United States","volume":"4","author":"Chari A","year":"2020","unstructured":"Chari A , HagiwaraM, KeeAet al. Recent treatment patterns, healthcare utilization, and costs in heavily pretreated relapsed and\/or refractory multiple myeloma patients in the United States. HemaSphere4(Suppl. 1), EP1756 (2020).","journal-title":"HemaSphere"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e20543"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S105613"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:51Z","timestamp":1719125211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/fon-2020-1003"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1003","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}